Uncategorized
Replicor to present interim REP 2055 clinical efficacy data at the 20th annual meeting of the APASL in Beijing, China
REPLICor to present interim REP 9AC clinical efficacy data at the 20th annual meeting of the APASL in Beijing, China Montreal, Quebec – March 18, 2010 – Replicor will present results from its clinical proof of concept trial at the upcoming 20th annual meeting of the APASL in Beijing, China. This is the largest annual…
Read MoreDr. Allison Jilbert presents preclinical efficacy data for REP 2055 in DHBV infected Pekin ducks
December 8, 2009 – Dr. Allison Jilbert from University of Adelaide, Australia, will present our preclinical efficacy data on REP 2055 at the HEP DART 2009 conference to be held in Hawaii on December 6 – 10, 2009. This conference is attended by hundreds of physicians and researchers from pharmaceutical companies and universities worldwide who…
Read MoreReplicor publishes data on the activity and safety of amphipathic DNA polymers (APs) in cytomegalovirus infection
December 2, 2009 – Data generated in collaboration with the Cincinnati Children’s Hospital and funded in part by the NIH was published in Virology Journal. This article presents data that demonstrates that several different amphipathic DNA polymers (APs) are highly effective in protecting mice from developing CMV infections. APs were effective whether administered parenterally or…
Read MorePublication of Replicor’s first in class HCV entry inhibitor based on its amphipathic DNA polymer technology
April 23, 2009 – The results of a collaboration between Replicor and the lab of Dr. Jake Liang from the Liver Diseases Branch of the National Institutes of Health (NIH) were published today in the prestigious journal Gastroenterology. This article details the activity of Replicor’s technology against numerous genotypes of HCV in vitro and also…
Read MoreReplicor publishes data on mechanism of action and pre-clinical efficacy of amphipathic DNA polymers (APs) in HCV infection
April 16, 2009 – Data generated in collaboration with the Liver Diseases Branch of the NIH was published in the prestigious journal Gastroenterology. The article presented data that demonstrated that numerous different amphipathic DNA polymers (APs) were effective in vitro against HCV infection from all known genotypes, using both JFH1 and pseudoparticle systems. APs were…
Read MoreReplicor to present preclinical data showing a curative response to hepatitis B infection with its drug at the 1st Annual Girindus Leaders in Oligonucletides Meeting
March 31, 2009 — Dr. Andrew Vaillant, Chief Scientific Officer, has been invited to present Replicor’s latest preclinical data on the use of its drug for the treatment of hepatitis B. This presentation will include the latest data from Replicor’s collaboration with the lab of Dr. Allison Jilbert and will demonstrate for the first time…
Read MoreReplicor initiates dosing of human patients with its drug
March 2009 — Under its IRB-approved protocol, Replicor initiated treatment of patients enrolled in its phase I / II trial with its drug.
Read MoreReplicor receives IRB approval to conduct a phase I / II trial to test the safety and efficacy of its drug in patients with chronic hepatitis B and hepatitis C.
February 2009 — Replicor announced today that it has received approval to conduct an open label study of the safety and efficacy of its drug in patients with chronic hepatitis B and C in Asia. Patients will receive escalating doses of the drug to determine a safe and effective dose of its drug for treating…
Read More